Les Laboratoires Servier
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Les Laboratoires Servier
InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.
Therapyx and Intravacc are optimizing a candidate gonorrhea vaccine following promising results in primates and the granting of a three-year SBIR award by the US NIAID.
It has taken a while but European regulators have finally followed their US counterparts and approved Piqray, making it the first targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation.
The coronavirus research field may be dominated by vaccines from the likes of Oxford University/AstraZeneca and Pfizer/BioNTech, but a lot of interesting work is being done elsewhere by smaller academic and commercial projects looking at the potential of various novel antibody therapies against COVID-19.
- Generic Drugs
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Biogaran SAS
- Egis Pharmaceuticals plc
- Servier BioInnovation
- Symphogen A/S